Introduction: We expanded upon our previous experience using involved-field fractionated radiotherapy (IFRT) as an alternative to whole brain radiotherapy or stereotactic radiosurgery for patients with surgically resected brain metastases (BM).
Materials And Methods: All patients with single BM who underwent surgical resection followed by IFRT at our institution from 2006 to 2013 were evaluated. Local recurrence (LR)-free survival, distant failure (DF)-free survival, and overall survival (OS) were determined. Analyses were performed associating clinical variables with LR and DF. Salvage approaches and toxicity of treatment for each patient were also assessed.
Results: Median follow-up was 19.1 months. Fifty-six patients were treated with a median dose of 40.05 Gy/15 fractions with IFRT to the resection cavity. LR-free survival was 91.4%, DF-free survival was 68.4%, and OS was 77.7% at 12 months. No variables were associated with increased LR; however, melanoma histopathology and infratentorial location were associated with DF on multivariate analysis. LRs were salvaged in 5/8 patients, and DFs were salvaged in 24/29 patients. Two patients developed radionecrosis.
Conclusion: Adjuvant IFRT is feasible and safe for well-selected patients with surgically resected single BM. Acceptable rates of local control and salvage of distal intracranial recurrences continue to be achieved with continued follow-up.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4585114 | PMC |
| http://dx.doi.org/10.3389/fonc.2015.00206 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Safety and early efficacy of involved-field SBRT for nodal oligo-recurrent prostate cancer.
Front Oncol
October 2024
Department of Radiation Medicine, Georgetown University Hospital, Washington, DC, United States.
Purpose: Following treatment for localized prostate cancer, a subset of men will develop recurrent disease in the abdominopelvic nodes. For radiation therapy (RT), the optimal treatment volume, fractionation schedule, and dose remain unanswered questions. We report early outcomes for patients treated with involved-field stereotactic body radiation therapy (SBRT) (IF-SBRT) for nodal oligo-recurrent (NOR) prostate cancer.
View Article and Find Full Text PDFInvolved-field high-dose chemoradiotherapy with respiratory motion management for esophageal squamous cell carcinoma.
Thorac Cancer
November 2024
Department of Radiology, University of Yamanashi, Chūō, Yamanashi, Japan.
Article Synopsis
- The study analyzed the effects of high-dose chemoradiotherapy combined with respiratory motion management on patients with esophageal squamous cell carcinoma (ESCC) between 2012 and 2018.
- Out of 35 patients, the treatment showed a high overall response rate of 94.3%, with a median follow-up of 43 months, but significant survival differences were noted based on the presence of esophageal fistulas.
- While the treatment was generally effective, it also resulted in major toxicities, especially decreased blood cell counts, indicating the need for careful consideration of risks like esophageal fistulas in future candidates.
Adebrelimab plus chemotherapy and sequential thoracic radiotherapy as first-line therapy for extensive-stage small-cell lung cancer (ES-SCLC): a phase II trial.
EClinicalMedicine
September 2024
Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Background: This phase II prospective trial aimed to investigate the efficacy and safety of adebrelimab (PD-L1 antibody) plus first-line chemotherapy followed by sequential thoracic radiotherapy (TRT) combined with adebrelimab in extensive-stage small-cell lung cancer (ES-SCLC). Biomarkers associated with potential therapeutic effects were also explored.
Methods: Patients with previously untreated ES-SCLC were enrolled at Shandong Cancer Hospital and Institute (Jinan, China).
Radiotherapy with S-1 for the treatment of esophageal squamous cell carcinoma 75 years or older.
Radiat Oncol
August 2024
Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, No. 42, Baizitng, Xuanwu District, Nanjing, 210009, China.
Objective: Explore the efficacy and safety of involved-field irradiation (IFI) combined with S-1 as definitive concurrent chemoradiotherapy (dCRT) for locally advanced elderly esophageal squamous cell carcinoma (ESCC), under the premise of intensity-modulated radiotherapy (IMRT).
Methods: We designed a prospective single-arm phase II study. The study enrolled 91 patients aged 75 to 92 years.
Dosimetric comparison of nodal clinical target volume for locally advanced non‑small cell lung cancer: Options for geometric expansion vs. lymph node stations.
Mol Clin Oncol
August 2024
Department of Radiation Oncology, Kagawa University Hospital, Miki, Kagawa 761-0793, Japan.
Article Synopsis
- The study aimed to assess dosimetric differences in nodal clinical target volume (CTV) for locally advanced non-small cell lung cancer (NSCLC) by comparing geometric expansion and lymph node (LN) station-based approaches based on European guidelines.
- Results showed that the geometric expansion method resulted in significantly lower doses and volumes of radiation affecting the esophagus, lungs, and heart compared to the LN station approach.
- Additionally, patients with LN metastases in certain stations experienced more significant differences in lung volume radiation exposure when using geometric expansion, suggesting it may be a better option for reducing radiation dose.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!